Search Within

Neil Howard Segal

Formats
  1. Meeting Abstract (111)
  2. Journal Article (97)
  3. Review (2)
  4. Book Section (1)
  5. Miscellaneous (1)
  6. Research Letter (1)
Groups
  1. Department of Medicine (213)
  2. Gastrointestinal Oncology Service (213)
  3. Solid Tumor Oncology Division (213)
  4. Center for Pancreatic Cancer Research (98)
  5. Surgery (81)
  6. Survivorship Research (80)

More Groups

People
  1. Leonard Saltz (82)
  2. Andrea Cercek Hanjis (70)
  3. Zsofia Stadler (67)
  4. Martin Weiser (61)
  5. Rona Yaeger (61)
  6. Jinru Shia (56)

More People

Years
  1. 2025 (9)
  2. 2024 (15)
  3. 2023 (12)
  4. 2022 (14)
  5. 2021 (11)
  6. 2020 (10)

More Years

Publications
  1. Journal of Clinical Oncology (78)
  2. Annals of Oncology (22)
  3. Clinical Cancer Research (9)
  4. Cancer Research (6)
  5. Journal for ImmunoTherapy of Cancer (6)
  6. Modern Pathology (6)

More Publications

Publishers
  1. American Society of Clinical Oncology (83)
  2. Oxford University Press (27)
  3. American Association for Cancer Research (21)
  4. Elsevier Inc. (19)
  5. Nature Publishing Group (10)
  6. Biomed Central Ltd (6)

More Publishers

Results (213)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma
    Journal Article

    Lee, L. H.; Cavalcanti, M. S.; Segal, N. H.; Hechtman, J. F.; Weiser, M. R.; Smith, J. J.; Garcia-Aguilar, J.; Sadot, E.; Ntiamoah, P.; Markowitz, A. J.; more...
    Modern Pathology (2016)

    Fulltext@MSK | Save
  • A phase II efficacy and safety, open-label, multicenter study of imprime PGG injection in combination with cetuximab in patients with stage IV KRAS-mutant colorectal cancer
    Journal Article

    Segal, N. H.; Gada, P.; Senzer, N.; Gargano, M. A.; Patchen, M. L.; Saltz, L. B.
    Clinical Colorectal Cancer (2016)

    Fulltext@MSK | Save
  • Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer
    Journal Article

    Massard, C.; Gordon, M. S.; Sharma, S.; Rafii, S.; Wainberg, Z. A.; Luke, J.; Curiel, T. J.; Colon-Otero, G.; Hamid, O.; Sanborn, R. E.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Clinical prognostic factors and genomic analysis of ovary metastases (mets) from colorectal cancer (CRC)
    Meeting Abstract

    Ganesh, K.; Shah, R.; Vakiani, E.; Kemeny, N. E.; Lincoln, A.; Tran, C.; Varghese, A. M.; Yaeger, R. D.; Cercek, A.; Segal, N. H.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1
    Journal Article

    Naidoo, J.; Schindler, K.; Querfeld, C.; Busam, K.; Cunningham, J.; Page, D. B.; Postow, M. A.; Weinstein, A.; Lucas, A. S.; Ciccolini, K. T.; more...
    Cancer Immunology Research (2016)

    Fulltext@MSK | Save
  • Safety and clinical activity of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Antonia, S.; Rizvi, N.; Brahmer, J.; Ou, S. H.; Khleif, S. N.; Hwu, W. J.; Gutierrez, M.; Schoffski, P.; Hamid, O.; Weiss, J.; more...
    Cancer Immunology Research (2016)

    Fulltext@MSK | Save
  • Reliable detection of mismatch repair deficiency in colorectal cancers using mutational load in next-generation sequencing panels
    Journal Article

    Stadler, Z. K.; Battaglin, F.; Middha, S.; Hechtman, J. F.; Tran, C.; Cercek, A.; Yaeger, R.; Segal, N. H.; Varghese, A. M.; Reidy-Lagunes, D. L.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Faster FOLFOX: Oxaliplatin can be safely infused at a rate of 1 mg/m(2)/min
    Journal Article

    Cercek, A.; Park, V.; Yaeger, R.; Reidy-Lagunes, D.; Kemeny, N. E.; Stadler, Z. K.; Segal, N. H.; Varghese, A.; Saltz, L. B.
    Journal of Oncology Practice (2016)

    Fulltext@MSK | Save
  • Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
    Journal Article

    Belum, V. R.; Benhuri, B.; Postow, M. A.; Hellmann, M. D.; Lesokhin, A. M.; Segal, N. H.; Motzer, R. J.; Wu, S.; Busam, K. J.; Wolchok, J. D.; more...
    European Journal of Cancer (2016)

    Fulltext@MSK | Save
  • An intimate dance: Patterns and clinical relevance of PD-L1 and PD-1 expression in colorectal carcinoma
    Meeting Abstract

    Lee, L. H.; Cavalcanti, M. S.; Segal, N.; Hechtman, J.; Vakiani, E.; Klimstra, D.; Shia, J. R.
    Modern Pathology (2016)

    Fulltext@MSK | Save